Answers are grounded in this paper and cite their sources.
Demonstrates IL-10 mRNA delivery improves outcomes in rats with pulmonary hypertension, suggesting new therapeutic strategies.
Pulmonary hypertension is a lethal condition characterized by an enhanced inflammatory response in the lungs. Cytokines such as interleukin-10 (IL-10) have demonstrated considerable potential as potent inflammation suppressors. Especially, with pulmonary hypertension patients showing diminished IL-10 levels. However, off-target toxicity poses a major limitation to their applications. Here we report a strategy in which IL-10 mRNA, encapsulated in extracellular vesicles, is delivered by inhalation. Targeted delivery to lung with preferential uptake reduces systemic side effects. IL-10 mRNA exerts selective immunomodulatory effects by suppressing inflammatory cytokine secretion and promoting apoptosis in M1-like pulmonary macrophages while sparing M2-like macrophages. This macrophage subset-specific regulation reshapes the pulmonary cytokine microenvironment, significantly down-regulating factors that promote pulmonary hypertension progression and ultimately inhibiting disease progression. The strategy was demonstrated in the sugen5416/hypoxia-induced rat model of pulmonary hypertension, providing substantial protection against disease progression. This shows the potential for locally delivered cytokine-based immunosuppressive therapies for inflammatory lung diseases.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: